Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials

Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials

BackgroundRelapsing multiple sclerosis (RMS) is a chronic, inflammatory disease of the central nervous system. Ublituximab, an anti-CD20 monoclonal antibody (mAb), is indicated for the treatment of RMS. We performed a systematic literature review (SLR) to identify randomized trials reporting the cli...

Full description

Saved in:
Bibliographic Details
Main Authors: Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Amir Ansaripour, Wallace Brownlee, David Paling, Mehdi Javanbakht
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Neurology
Subjects:
relapsing multiple sclerosis
relapsing-remitting
secondary progressive
monoclonal antibodies
ublituximab
systematic review
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1479476/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2024.1479476/full

Similar Items